John Birch has been appointed as a non-executive director to Cobra Biologics’ board to support expansion plans. Cobra has increased capacity in the past year, along with a 40% increase in headcount.
Mr. Birch previously served as chief scientific officer for Lonza Biopharmaceuticals. In his new role, he will provide his experience and expertise in the CMO sector and will focus Cobra’s efforts to expand its service offering and capabilities.
Peter Coleman, chief executive officer of Cobra Biologics, said, “I am extremely pleased that John has decided to join Cobra’s board at a very exciting time for the company and our customers. We have set ourselves ambitious expansion targets for the year and our success has meant rapid recruitment to sustain the increased number of customer projects coming through. The board and I look forward to working with John and our new employees to achieve our ambitious goals.”